Summary
AbbVie Inc. reported strong financial performance for the first quarter of 2017, with net revenues reaching $6.5 billion, a 9.7% increase year-over-year. This growth was primarily driven by a 15.1% increase in Humira sales, which continue to be the company's flagship product, and a significant 44.7% surge in Imbruvica sales. Despite strong top-line growth, operating earnings saw a modest increase to $2.4 billion, with diluted earnings per share reported at $1.06. The company continues to invest heavily in its R&D pipeline, with expenses increasing by 20% year-over-year to $1.1 billion, reflecting a strategic focus on immunology, oncology, virology, and neurology. AbbVie also demonstrated a commitment to returning capital to shareholders through substantial dividend payments and share repurchases, highlighting a balanced approach to growth and shareholder value. Key financial activities included managing foreign currency fluctuations and contingent consideration related to recent acquisitions. While the company experienced a decrease in sales for Viekira, this was offset by broad-based growth across its key franchises. Overall, AbbVie presented a robust quarter characterized by strong product performance and strategic pipeline development.
Financial Highlights
51 data points| Revenue | $6.54B |
| Cost of Revenue | $1.62B |
| Gross Profit | $4.92B |
| SG&A Expenses | $1.37B |
| Operating Expenses | $4.13B |
| Operating Income | $2.41B |
| Interest Expense | $273.00M |
| Net Income | $1.71B |
| EPS (Basic) | $1.07 |
| EPS (Diluted) | $1.06 |
| Shares Outstanding (Basic) | 1.60B |
| Shares Outstanding (Diluted) | 1.60B |
Key Highlights
- 1AbbVie reported a 9.7% increase in net revenues to $6.5 billion for the first quarter of 2017, compared to $5.9 billion in the prior year.
- 2Humira sales grew by 15.1% to $4.1 billion, demonstrating continued strong performance and market leadership.
- 3Imbruvica sales experienced substantial growth of 44.7%, reaching $551 million, driven by expanded indications and market penetration.
- 4Research and Development expenses increased by 20% to $1.1 billion, reflecting ongoing investment in pipeline development.
- 5Diluted Earnings Per Share (EPS) was $1.06, with the quarter's results impacted by amortization of intangibles, changes in contingent consideration, and milestone payments.
- 6The company returned $1.0 billion to shareholders through dividends and repurchased approximately 7.8 million shares for $500 million.
- 7Net foreign exchange loss significantly decreased from $302 million in Q1 2016 to $13 million in Q1 2017, largely due to the resolution of Venezuelan currency issues.